
Outsmarting brain cancer
The approach, studied in mice, overcomes the blood brain barrier and breaks the shield tumors build against the immune response.
Fawcett leads a team of communicators who produce targeted, innovative communication for the Rogel Cancer Center’s research and clinical enterprises. Prior to Michigan Medicine, Fawcett was a reporter at the Detroit News and editor for a web-based community for people with disabilities.
The approach, studied in mice, overcomes the blood brain barrier and breaks the shield tumors build against the immune response.
A survey of young adult cancer survivors illustrates the compromises people make when asking family, friends for financial support during cancer treatment.
Nearly 2 decades after a groundbreaking discovery, Arul Chinnaiyan wins a prestigious cancer research award.
A chromatin degrader stops transcription factors from driving cancer, which may serve as a potential treatment approach for over 90% of prostate cancers.
HPV circulating tumor DNA and MRI/PET imaging markers predicted which tumors would respond to chemoradiation as early as two weeks into treatment.
Bolstering a specific enzyme within the mitochondria of intestinal cells helped mitigate GI disease induced by T cells after bone marrow transplant, cancer immunotherapy.